Virological failure is defined as any viral load greater than 1000 copies/mL (≥log3), after at least 6 months of treatment. The study focused on the assessment of the level of treatment failure in people living with HIV on antiretroviral treatment in Chad. This was an analytical and descriptive prospective study conducted between July 2021 and July 2022. The determination of the filler was carried out by the Reaction Chain Polymerization (PCR) method with kit Generic HIV Viral Load？ (Biocentric, Bandol, France) and the Xpert HIV-1 Viral Load？ Kit (Cepheid, Maurens-Scopont, France) on Genexpert. During the study, 4890 patients benefited from viral loads, including 3443 (70.4%) women and 1447 (29.6%) men. The majority of patients were married (60.9%), followed by single (16.6%), divorced (13.9%) and widowed (8.6%). The ratio of 2.4 in favor of women. Of all the patients included, 881 (18.0%) were in virological failure, of which 59.6% were married, 22% were single, 12.1% were divorced and 6.2% were widowed. Of these, 50.3% (444/881) were on TDF/FTC/EFV, 37.7% (333/881) were on TDF/3TC/DTG, 3.9% (35/881) on TDF/FTC/ATZ, 2.9% (26/881) were on AZT/3TC/EFV-based diet, 1.9% (17/881) were on ABC/3TC/LPV-based diet, 1.5% (14/881) were on TDF/FTC-based diet, and 1.3% (12/881) were on ABC/3TC/ATV-based diet. The majority of patients had been on treatment for between five (05) and ten (10) years, respectively 52.7% (2578/4890) and 32.8% (1603/4890). 13.9% (680/4890) had been on treatment for fifteen (15) years and 0.6% (28/4889) had been on treatment for more than twenty (20) years. In patients with virological failure, 0.5% (4/881) of patients with treatment failure had been on treatment for more than 20 years, 11.9% (105/881) had been on treatment for more than 15 years, 54.9% (484/881) had been on treatment for less than 10 years 32.7% (288/881) had been on treatment for less than 5 years. The compliance rate was 3.7% (179/4890) in all patients. It is 4.3% (38/881) in patients with treatment failure. Treatment failure is a burden for the patient on antiretroviral therapy, as the drug fails to control the virus and key organs continue to be poisoned.
References
[1]
Endalamaw, A., et al. (2023) HIV/AIDS Treatment Failure and Associated Factors in Ethiopia: Meta-Analysis. BMC Public Health, 20, Article No. 82. https://pubmed.ncbi.nlm.nih.gov/31959136/
[2]
UNAIDS (2022) Afrique de l’Ouest et du Centre: Un Sommet régional sur le VIH vise à renforcer la riposte au virus|ONU Info. https://news.un.org/fr/story/2021/11/1107502
[3]
Ministére de la Santé Publique et de la Prevention (2022) Annuaire des statistiques sanitaires. Tome A.
[4]
Lailulo, Y., Kitenge, M., Jaffer, S., Aluko, O. and Nyasulu, P.S. (2020) Factors Associated with Antiretroviral Treatment Failure among People Living with HIV on Antiretroviral Therapy in Resource-Poor Settings: A Systematic Review and Meta-Analysis. SystematicReviews, 9, Article No. 292. https://doi.org/10.1186/s13643-020-01524-1
[5]
Adawaye, C., Fokam, J., Kamangu, E., Alio, H.M., Chahad, A.M., Susin, F., et al. (2017) Virological Response, HIV-1 Drug Resistance Mutations and Genetic Diversity among Patients on First-Line Antiretroviral Therapy in N’Djamena, Chad: Findings from a Cross-Sectional Study. BMCResearchNotes, 10, Article No. 589. https://doi.org/10.1186/s13104-017-2893-1
[6]
OMS (2021) La résistance du VIH aux médicaments s’accroît|AfriqueRenouveau. https://www.un.org/africarenewal/fr/magazine/la-r%C3%A9sistance-du-vih-aux-m%C3%A9dicaments-saccro%C3%AEt
[7]
Yu, F., Li, Q., Wang, L., Zhao, H., Wu, H., Yang, S., et al. (2022) Drug Resistance to HIV-1 Integrase Inhibitors among Treatment-Naive Patients in Beijing, China. PharmacogenomicsandPersonalizedMedicine, 15, 195-203. https://doi.org/10.2147/pgpm.s345797
[8]
Ayitewala, A., Kyeyune, F., Ainembabazi, P., Nabulime, E., Kato, C.D. and Nankya, I. (2020) Comparison of HIV Drug Resistance Profiles across HIV-1 Subtypes a and D for Patients Receiving a Tenofovir-Based and Zidovudine-Based First Line Regimens in Uganda. AIDSResearchandTherapy, 17, Article No. 2. https://doi.org/10.1186/s12981-020-0258-7
[9]
Wadonda-Kabondo, N., Hedt, B.L., van Oosterhout, J.J., Moyo, K., Limbambala, E., Bello, G., et al. (2012) A Retrospective Survey of HIV Drug Resistance among Patients 1 Year after Initiation of Antiretroviral Therapy at 4 Clinics in Malawi. ClinicalInfectiousDiseases, 54, S355-S361. https://doi.org/10.1093/cid/cis004
[10]
Stockdale, A.J., Chaponda, M., Beloukas, A., Phillips, R.O., Matthews, P.C., Papadimitropoulos, A., et al. (2017) Prevalence of Hepatitis D Virus Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. TheLancetGlobalHealth, 5, e992-e1003. https://doi.org/10.1016/s2214-109x(17)30298-x
[11]
Fofana, D.B., d’Almeida, M., Lambert-Niclot, S., Peytavin, G., Girard, P.M., Lafia, B., et al. (2018) Resistance Profile and Treatment Outcomes in HIV-Infected Children at Virological Failure in Benin, West Africa. JournalofAntimicrobialChemotherapy, 73, 3143-3147. https://doi.org/10.1093/jac/dky300
[12]
Fofana, D.B., Diarra, H., Guindo, I., Savadogo, M.K., d’Almeida, M., Diallo, F.I., et al. (2023) Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children. Viruses, 15, Article No. 546. https://doi.org/10.3390/v15020546
[13]
OMS (2022) Une charge virale indétectable, une meilleure santé des personnes vivant avec le VIH|OMS|Bureau régional pour l’Afrique. https://www.afro.who.int/fr/countries/chad/news/une-charge-virale-indetectable-une-meilleure-sante-des-personnes-vivant-avec-le-vih
[14]
Hauser, A., Goldstein, F., Reichmuth, M.L., Kouyos, R.D., Wandeler, G., Egger, M., et al. (2022) Acquired HIV Drug Resistance Mutations on First-Line Antiretroviral Therapy in Southern Africa: Systematic Review and Bayesian Evidence Synthesis. JournalofClinicalEpidemiology, 148, 135-145. https://doi.org/10.1016/j.jclinepi.2022.02.005
[15]
Boender, T.S., Kityo, C.M., Boerma, R.S., Hamers, R.L., Ondoa, P., Wellington, M., et al. (2016) Accumulation of HIV-1 Drug Resistance after Continued Virological Failure on First-Line ART in Adults and Children in Sub-Saharan Africa. JournalofAntimicrobialChemotherapy, 71, 2918-2927. https://doi.org/10.1093/jac/dkw218
[16]
Fred, K., Richard, M.G., Immaculate, N., Cissy, M.K., Robert, A., Peter, M., et al. (2016) Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Antimicrobial Agents and Chemotherapy, 60, 3380-3397. https://pubmed.ncbi.nlm.nih.gov/27001818/
[17]
WHO Publishes New Consolidated HIV Guidelines for Prevention, Treatment, Service Delivery & Monitoring. https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring
[18]
Endalamaw, A., Mekonnen, M., Geremew, D., Yehualashet, F.A., Tesera, H. and Habtewold, T.D. (2020) HIV/AIDS Treatment Failure and Associated Factors in Ethiopia: Meta-Analysis. BMCPublicHealth, 20, Article No. 82. https://doi.org/10.1186/s12889-020-8160-8
[19]
Henry, T. (2017) Un prêche islamique sur la prévention de l’infection par le VIH. https://hal.science/halshs-01634422/
[20]
Gomez, C., Madrigal-Cadavid, J., Giraldo, P.A., Abad, J.M., Serna, J.A., Segura, Á., et al. (2022) Factors Associated with Virologic Failure in HIV Patients on Antiretroviral Therapy. Farmacia Hospitalaria, 46, 282-289.
[21]
Oumar, A.A., Marie, C.M., Seydou, M.C., Bassirou, D., Yacouba, C., Aliou, B., et al. (2019) Observance thérapeutique des antirétroviraux chez les patients suivis au chu du point g: Comparaison de deux méthodes de mesure, objective et subjective. RevueMaliennedeScienceetdeTechnologie, 21, 95-108. https://revues.ml/index.php/rmst/article/view/1242
[22]
Bezabih, Y.M., Beyene, F. and Bezabhe, W.M. (2019) Factors Associated with First-Line Antiretroviral Treatment Failure in Adult HIV-Positive Patients: A Case-Control Study from Ethiopia. BMCInfectiousDiseases, 19, Article No. 537. https://doi.org/10.1186/s12879-019-4170-5
[23]
Thome, L., Billong, S., Penda, C., Fokam, J., Akaba, D., Zoung-Kanyi, A., et al. (2019) Échec thérapeutique, résistance acquise du VIH chez les adultes sous traitement ARV de 2ème ligne Article Original Échec Thérapeutique, Résistance Acquise du VIH et Souches Virales chez les Adultes sous Traitement Antirétroviral de Deuxième Ligne au Cameroun: Étude sur 18 ans (1999-2017) de Monitorage à l’Hôpital Central de Yaoundé Profile of HIV Drug Resistance and Viral Strains among Cameroonian Patients Receiving a Second-Line ART: An 18 Year Study.
[24]
Bayu, B., Tariku, A., Bulti, A., Habitu, Y., Derso, T. and Teshome, D. (2017) Determinants of Virological Failure among Patients on Highly Active Antiretroviral Therapy in University of Gondar Referral Hospital, Northwest Ethiopia: A Case-Control Study. HIV/AIDS—ResearchandPalliativeCare, 9, 153-159. https://doi.org/10.2147/hiv.s139516
[25]
Keita, A., Djimera, N., Djarma, O., N’Guyen, Y., Bourlet, T. and Andréoletti, L. (2020) Primary Resistance to Antiretroviral Drugs of HIV Strains in Chad: A Retrospective Investigation by Analysis of Frozen Dried Blood Spot Samples. European Journal of Clinical Microbiology & Infectious Diseases, 40, 1091-1095.
[26]
Cisse, V., Niang, I., Diallo, K., Senghor, G., Diop, S. and Manga, N. (2019) Facteurs associés à l’échec virologique chez les patients infectés par le VIH suivis dans le district sanitaire de Oussouye, région de Ziguinchor au Sénégal. MédecineetMaladiesInfectieuses, 49, S146. https://doi.org/10.1016/j.medmal.2019.04.351
[27]
Cahn, P., Sierra Madero, J., Arribas, J.R., Antinori, A., Ortiz, R., Clarke, A.E., et al. (2021) Three-Year Durable Efficacy of Dolutegravir plus Lamivudine in Antiretroviral Therapy—Naive Adults with HIV-1 Infection. Aids, 36, 39-48. https://doi.org/10.1097/qad.0000000000003070
[28]
Psichogiou, M., Poulakou, G., Basoulis, D., Paraskevis, D., Markogiannakis, A. and Daikos, G.L. (2017) Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors. CurrentPharmaceuticalDesign, 23, 2552-2567. https://doi.org/10.2174/1381612823666170329142059
[29]
Labhardt, N.D., Bader, J., Lejone, T.I., Ringera, I., Puga, D., Glass, T.R., et al. (2015) Is Zidovudine First-Line Therapy Virologically Comparable to Tenofovir in Resource-Limited Settings? TropicalMedicine&InternationalHealth, 20, 914-918. https://doi.org/10.1111/tmi.12509
